Zobrazeno 1 - 10
of 264
pro vyhledávání: '"Toni K. Choueiri"'
Autor:
Harish Seethapathy, Sarah Street, Xiao Wei, Shveta S. Motwani, Kerry L. Reynolds, Toni K. Choueiri, Nifasha Rusibamayila, Ian A. Strohbehn, Meghan Lee, M.D. Michaelson, Brad McGregor, Cristina Salabao, Guru Sonpavde, Meghan E. Sise, David E. Leaf, Shruti Gupta, Sophia H. Zhao, Donald F. Chute, Xin Gao, Marina D. Kaymakcalan, Osama E. Rahma
Publikováno v:
European Journal of Cancer. 157:50-58
Background In patients with genitourinary cancers, the effect of immune checkpoint inhibitors (ICIs) on kidney function is unknown. Patients and methods This is a retrospective cohort study of patients with renal cell carcinoma (RCC) and urothelial c
Autor:
Christian Kollmannsberger, Ben Tran, Aaron R. Hansen, Guillermo Velasco, Daniel Y.C. Heng, Daniel Vilarim Araujo, M. Neil Reaume, Takeshi Yuasa, Connor Wells, Georg A. Bjarnason, Benoit Beuselinck, Chun Loo Gan, D. Scott Ernst, Flora Yan, Shaan Dudani, Frede Donskov, Sumanta K. Pal, Thomas Powles, Nazli Dizman, Toni K. Choueiri
Publikováno v:
Araujo, D V, Wells, J C, Hansen, A R, Dizman, N, Pal, S K, Beuselinck, B, Donskov, F, Gan, C L, Yan, F, Tran, B, Kollmannsberger, C K, de Velasco, G, Yuasa, T, Reaume, M N, Ernst, D S, Powles, T, Bjarnason, G A, Choueiri, T K, Heng, D Y C & Dudani, S 2021, ' Efficacy of immune-checkpoint inhibitors (ICI) in the treatment of older adults with metastatic renal cell carcinoma (mRCC) – an International mRCC Database Consortium (IMDC) analysis ', Journal of Geriatric Oncology, vol. 12, no. 5, pp. 820-826 . https://doi.org/10.1016/j.jgo.2021.02.022
5068 Background: Anti-PD-1/PD-L1 immune-checkpoint inhibitors (ICI) are now a standard of care in metastatic renal cell carcinoma (mRCC). Older adults were underrepresented in registration trials and given that immunological senescence may affect the
Autor:
Toni K, Choueiri, Thomas, Powles, Mauricio, Burotto, Bernard, Escudier, Maria T, Bourlon, Bogdan, Zurawski, Victor M, Oyervides Juárez, James J, Hsieh, Umberto, Basso, Amishi Y, Shah, Cristina, Suárez, Alketa, Hamzaj, Jeffrey C, Goh, Carlos, Barrios, Martin, Richardet, Camillo, Porta, Rubén, Kowalyszyn, Juan P, Feregrino, Jakub, Żołnierek, David, Pook, Elizabeth R, Kessler, Yoshihiko, Tomita, Ryuichi, Mizuno, Jens, Bedke, Joshua, Zhang, Matthew A, Maurer, Burcin, Simsek, Flavia, Ejzykowicz, Gisela M, Schwab, Andrea B, Apolo, Robert J, Motzer, Suresh, Nair
Publikováno v:
New England Journal of Medicine. 384:829-841
The efficacy and safety of nivolumab plus cabozantinib as compared with those of sunitinib in the treatment of previously untreated advanced renal-cell carcinoma are not known.In this phase 3, randomized, open-label trial, we randomly assigned adults
Autor:
Nazli Dizman, Bernadett Szabados, Sumanta K. Pal, Frede Donskov, Toni K. Choueiri, Guillermo Velasco, Benoit Beuselinck, Chun Loo Gan, Daniel Y.C. Heng, Aly-Khan A. Lalani, Ulka N. Vaishampayan, J. Connor Wells, Aaron R. Hansen, Nityam Rathi, Georg A. Bjarnason, Ben Tran, Flora Yan, Shaan Dudani, Jae-Lyun Lee, Mathushan Subasri
Publikováno v:
Cancer Medicine
Cancer Medicine, Vol 10, Iss 4, Pp 1212-1221 (2021)
Gan, C L, Dudani, S, Wells, J C, Donskov, F, Pal, S K, Dizman, N, Rathi, N, Beuselinck, B, Yan, F, Lalani, A K A, Hansen, A, Szabados, B, de Velasco, G, Tran, B, Lee, J L, Vaishampayan, U N, Bjarnason, G A, Subasri, M, Choueiri, T K & Heng, D Y C 2021, ' Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma : Results from the International Metastatic Renal Cell Carcinoma Database Consortium ', Cancer Medicine, vol. 10, no. 4, pp. 1212-1221 . https://doi.org/10.1002/cam4.3717
Cancer Medicine, Vol 10, Iss 4, Pp 1212-1221 (2021)
Gan, C L, Dudani, S, Wells, J C, Donskov, F, Pal, S K, Dizman, N, Rathi, N, Beuselinck, B, Yan, F, Lalani, A K A, Hansen, A, Szabados, B, de Velasco, G, Tran, B, Lee, J L, Vaishampayan, U N, Bjarnason, G A, Subasri, M, Choueiri, T K & Heng, D Y C 2021, ' Cabozantinib real-world effectiveness in the first-through fourth-line settings for the treatment of metastatic renal cell carcinoma : Results from the International Metastatic Renal Cell Carcinoma Database Consortium ', Cancer Medicine, vol. 10, no. 4, pp. 1212-1221 . https://doi.org/10.1002/cam4.3717
Background Cabozantinib is approved for metastatic renal cell carcinoma (mRCC) based on the METEOR and CABOSUN trials. However, real‐world effectiveness and dosing patterns of cabozantinib are not well characterized. Methods Patients with mRCC trea
Autor:
Rana R. McKay, Lauren C. Harshman, David F. McDermott, Benjamin L. Maughan, Tracy L. Rose, Christos Kyriakopoulos, Bradley Alexander McGregor, Toni K. Choueiri, Walter M. Stadler, Yousef Zakharia, David A. Braun, Xiao Wei, Wanling Xie
Publikováno v:
J Clin Oncol
PURPOSE In this phase II response-adaptive trial, we investigated the rational application of immune checkpoint blockade in renal cell carcinoma (RCC; ClinicalTrials.gov identifier: NCT03203473 ). METHODS We enrolled patients with metastatic RCC with
Autor:
Bradley Rosbrook, Ulka N. Vaishampayan, Toni K. Choueiri, Saby George, David F. McDermott, Daniel C. Cho, Elizabeth R. Plimack, Igor Puzanov, Mayer Fishman, Jean-Francois Martini, Michael B. Atkins, Jamal Tarazi, Kathrine C. Fernandez
Publikováno v:
Clinical Cancer Research. 26:5598-5608
Purpose: Combined axitinib/pembrolizumab is approved for advanced renal cell carcinoma (aRCC). This exploratory analysis examined associations between angiogenic and immune-related biomarkers and outcomes following axitinib/pembrolizumab treatment. P
Autor:
Zhuoer Xie, Julie T Wu, Huili Zhu, Deborah B. Doroshow, Yu Shyr, Thorvardur R. Halfdanarson, Jessica Hawley, Sanjay Mishra, Lidia Schapira, Leslie A. Fecher, Sanjay Goel, Samuel M. Rubinstein, Petros Grivas, Pamela C Egan, Solange Peters, Sumit A. Shah, Gary K. Schwartz, Michael A. Thompson, Jonathan T Arcobello, Chih-Yuan Hsu, Christopher R. Friese, Dimitrios Farmakiotis, Corrie A. Painter, Matthew D. Galsky, Nicole M. Kuderer, Nathan A. Pennell, Ziad Bakouny, Sanjay G. Revankar, Brian I. Rini, Albert C. Yeh, Donna R. Rivera, Jeremy L. Warner, Dimpy P. Shah, Brendan J Lee, Ali Raza Khaki, Adam J. Olszewski, Matthew Puc, Orestis A. Panagiotou, Gary H. Lyman, Christopher Lemmon, Balazs Halmos, Andrew Schmidt, Toni K. Choueiri, Gilberto Lopes, Shilpa Gupta
Publikováno v:
Cancer Discovery
Cancer discovery, vol. 10, no. 10, pp. 1514-1527
Cancer discovery, vol. 10, no. 10, pp. 1514-1527
In a large observational study in patients with COVID-19 and cancer, survival was not significantly influenced by receipt of COVID-19 treatments, except hydroxychloroquine plus any other treatment, which was associated with reduced survival.
Amo
Amo
Publikováno v:
Clinical Genitourinary Cancer. 18:e598-e609
A growing body of evidence suggests that age and gender play a role in cancer outcomes. The objective of this study was to investigate the effect of age and gender on survival of patients with metastatic renal cell carcinoma (RCC).We conducted a pool
Autor:
Jessica E, Hawley, Tianyi, Sun, David D, Chism, Narjust, Duma, Julie C, Fu, Na Tosha N, Gatson, Sanjay, Mishra, Ryan H, Nguyen, Sonya A, Reid, Oscar K, Serrano, Sunny R K, Singh, Neeta K, Venepalli, Ziad, Bakouny, Babar, Bashir, Mehmet A, Bilen, Paolo F, Caimi, Toni K, Choueiri, Scott J, Dawsey, Leslie A, Fecher, Daniel B, Flora, Christopher R, Friese, Michael J, Glover, Cyndi J, Gonzalez, Sharad, Goyal, Thorvardur R, Halfdanarson, Dawn L, Hershman, Hina, Khan, Chris, Labaki, Mark A, Lewis, Rana R, McKay, Ian, Messing, Nathan A, Pennell, Matthew, Puc, Deepak, Ravindranathan, Terence D, Rhodes, Andrea V, Rivera, John, Roller, Gary K, Schwartz, Sumit A, Shah, Justin A, Shaya, Mitrianna, Streckfuss, Michael A, Thompson, Elizabeth M, Wulff-Burchfield, Zhuoer, Xie, Peter Paul, Yu, Jeremy L, Warner, Dimpy P, Shah, Benjamin, French, Clara, Hwang, Catherine, Stratton
Publikováno v:
JAMA network open. 5(1)
The COVID-19 pandemic has had a distinct spatiotemporal pattern in the United States. Patients with cancer are at higher risk of severe complications from COVID-19, but it is not well known whether COVID-19 outcomes in this patient population were as
Autor:
Toni K. Choueiri, Amin Nassar, Pier Vitale Nuzzo, Marina D. Kaymakcalan, David A. Braun, Mehmet Asim Bilen, Sarah Abou-Alaiwi, Dylan J. Martini, John A. Steinharter, Ziad Bakouny, Justin H. Fleischer, Aly-Khan A. Lalani, Xiao X. Wei, Wanling Xie, Bradley Alexander McGregor, Lauren C. Harshman
Publikováno v:
European Journal of Cancer. 135:203-210
Background Cabozantinib is approved for the first and subsequent line treatment of metastatic clear-cell renal cell carcinoma (ccRCC) based on trials in which most patients were immune checkpoint blockade (ICB) naive. With an expanding role of ICB in